Research Analysts’ Weekly Ratings Changes for IDEAYA Biosciences (IDYA)

A number of firms have modified their ratings and price targets on shares of IDEAYA Biosciences (NASDAQ: IDYA) recently:

• 11/9/2026 – IDEAYA Biosciences had its price target lowered by Mizuho from $44.00 to $39.00. They now have an “outperform” rating on the stock.
• 11/5/2026 – IDEAYA Biosciences had its price target raised by Citigroup from $65.00 to $66.00. They now have a “buy” rating on the stock.
• 11/4/2026 – IDEAYA Biosciences had its price target lowered by Royal Bank Of Canada from $48.00 to $45.00. They now have an “outperform” rating on the stock.
• 11/4/2026 – IDEAYA Biosciences had its price target lowered by Guggenheim from $57.00 to $52.00. They now have a “buy” rating on the stock.
• 11/4/2026 – IDEAYA Biosciences had its price target raised by Wedbush from $60.00 to $63.00. They now have an “outperform” rating on the stock.
• 11/3/2026 – IDEAYA Biosciences had its “buy” rating reaffirmed by Truist Financial. They now have a $57.00 price target on the stock, down from $59.00.
• 10/29/2026 – IDEAYA Biosciences was given a new $44.00 price target by Mizuho.
• 10/19/2026 – IDEAYA Biosciences had its “market outperform” rating reaffirmed by Citigroup.
• 10/16/2026 – IDEAYA Biosciences is now covered by William Blair. They set an “outperform” rating on the stock.
• 10/15/2026 – IDEAYA Biosciences had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/14/2026 – IDEAYA Biosciences is now covered by Stifel Nicolaus. They set a “buy” rating and a $48.00 price target on the stock.
• 9/22/2026 – IDEAYA Biosciences had its “overweight” rating reaffirmed by Cantor Fitzgerald.

IDEAYA Biosciences Stock Performance

Shares of IDYA opened at $31.75 on Wednesday. IDEAYA Biosciences, Inc. has a 52-week low of $26.81 and a 52-week high of $42.68. The firm has a market cap of $3.07 billion, a price-to-earnings ratio of -7.07 and a beta of 0.08. The business’s fifty day moving average is $35.95 and its 200-day moving average is $33.94.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported ($1.22) earnings per share for the quarter, missing the consensus estimate of ($1.18) by ($0.04). The business had revenue of $10.24 million for the quarter, compared to the consensus estimate of $7.58 million. IDEAYA Biosciences had a negative return on equity of 39.78% and a negative net margin of 1,157.18%. IDEAYA Biosciences’s quarterly revenue was up 14.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.33 earnings per share. As a group, research analysts forecast that IDEAYA Biosciences, Inc. will post -4.62 EPS for the current fiscal year.

Insider Activity at IDEAYA Biosciences

In other news, CEO Yujiro Hata sold 26,338 shares of the firm’s stock in a transaction that occurred on Tuesday, October 6th. The shares were sold at an average price of $37.41, for a total value of $985,304.58. Following the sale, the chief executive officer directly owned 690,695 shares in the company, valued at approximately $25,838,899.95. This trade represents a 3.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 4.70% of the company’s stock.

IDEAYA Biosciences, Inc. is a precision oncology company focused on discovering and developing targeted medicines for patients with cancer. Its research uses insights into tumor genetics and synthetic lethality—the idea that certain genetic changes can make cancer cells especially vulnerable to blocking a related biological pathway—to identify potential treatment targets. The company’s investigational pipeline includes small-molecule therapies aimed at specific cancer-related targets. Programs have included darovasertib, a protein kinase C inhibitor being studied in uveal melanoma, and IDE397, a MAT2A inhibitor being developed for tumors with particular genetic alterations.